
================================================================================
 CASE STUDY ANALYSIS - COMPREHENSIVE TEST (ALL 5 TABS)
================================================================================
  Drug: BARICITINIB
  Started: 2025-12-05 19:09:57.922390
  Output will be saved to: test_outputs\workflow_test_20251205_190957.txt

Initializing agent...
Agent ready.


================================================================================
 TAB 1: DRUG INFO FOR 'BARICITINIB'
================================================================================

  Drug Name:    baricitinib
  Generic Name: baricitinib
  Mechanism:    Janus Kinase Inhibitor
  Manufacturer: Eli Lilly and Company

  Approved Indications (4):
    1. adults with severe alopecia areata
    2. covid-19 in certain hospitalized adults
    3. adults with moderately-to-severely active rheumatoid arthritis
    4. moderately-to-severely active rheumatoid arthritis

--- Validation ---
  PASS: generic_name populated
  PASS: mechanism concise: 'Janus Kinase Inhibitor'
  PASS: Found 4 indications

================================================================================
 TAB 2: CASE SERIES SEARCH FOR 'BARICITINIB'
================================================================================

  Drug: baricitinib
  Exclude: ['adults with severe alopecia areata', 'covid-19 in certain hospitalized adults', 'adults with moderately-to-severely active rheumatoid arthritis']...

Searching... (may take 1-2 mins)

--- Results: 46 papers ---
  Full text (PMC): 25
  LLM verified: 46

  Diseases (34):
    - atopic dermatitis: 6
    - systemic lupus erythematosus: 3
    - adult-onset Still's disease: 3
    - juvenile idiopathic arthritis: 2
    - vitiligo: 2
    - atopic dermatitis (pediatric): 2
    - toxic epidermal necrolysis: 1
    - type 1 diabetes: 1
    - polymyalgia rheumatica: 1
    - lichen planus: 1
    - immune thrombocytopenia: 1
    - giant cell arteritis: 1
    - autoinflammatory type I interferonopathies: 1
    - lupus erythematosus panniculitis: 1
    - JAK1-associated inflammatory disease: 1

--- Sample Papers ---

  1. Baricitinib for systemic lupus erythematosus: a double-blind, randomis...
     PMID: 36848919 | Disease: systemic lupus erythematosus
     Full text: False
     Why: Phase 3 trial for baricitinib in SLE (off-label indication), no abstract but tit...

  2. Baricitinib decreases anti-dsDNA in patients with systemic lupus eryth...
     PMID: 35578304 | Disease: systemic lupus erythematosus
     Full text: True
     Why: Phase II trial in SLE patients with specific biomarker and efficacy outcomes, re...

  3. Baricitinib for systemic lupus erythematosus: a double-blind, randomis...
     PMID: 30043749 | Disease: systemic lupus erythematosus
     Full text: False
     Why: Phase 2 trial for baricitinib in SLE (off-label indication), no abstract but tit...

  4. Spatial proteomics identifies JAKi as treatment for a lethal skin dise...
     PMID: 39415009 | Disease: toxic epidermal necrolysis
     Full text: True
     Why: Study of toxic epidermal necrolysis with JAK inhibitor treatment including baric...

  5. Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diab...
     PMID: 38055252 | Disease: type 1 diabetes
     Full text: False
     Why: Study of baricitinib in new-onset type 1 diabetes evaluating β-cell function pre...

--- Validation ---
  PASS: Found 46 papers
  WARN: 4 potentially irrelevant papers
    - Off‐label use of rituximab for dermatologic condit...
    - A case of hemophagocytic lymphohistiocytosis with ...
    - Clinical and immunological study of Tofacitinib an...

================================================================================
 TAB 3: DATA EXTRACTION (WITH PMC FULL TEXT)
================================================================================

  Extracting from 25 papers with PMC full text...
  (This may take several minutes)

  1. [PMC] Baricitinib decreases anti-dsDNA in patients with syste...
     PASS: Disease=systemic lupus erythematosus, N=314, Response=None%
     Efficacy: Baricitinib demonstrated rapid and sustained reductions in anti-dsDNA antibodies...
     Safety: Safety outcomes were not reported in this analysis, which focused specifically o...

  2. [PMC] Spatial proteomics identifies JAKi as treatment for a l...
     PASS: Disease=Toxic epidermal necrolysis (TEN), N=7, Response=100.0%
     Efficacy: Treatment with JAK inhibitors including baricitinib was associated with rapid cu...
     Safety: Treatment with JAK inhibitors was described as safe in all seven patients with T...

  3. [PMC] Combination of Baricitinib and Phototherapy in Adults W...
     PASS: Disease=vitiligo, N=49, Response=None%
     Efficacy: Baricitinib combined with narrowband UV-B phototherapy demonstrated significant ...
     Safety: The abstract mentions tolerance of the combination therapy but specific safety d...

  4. [PMC] Efficacy and Safety of Baricitinib Combined With Topica...
     PASS: Disease=moderate to severe atopic dermatitis, N=329, Response=27.3%
     Efficacy: Both 2mg and 4mg baricitinib combined with topical corticosteroids showed superi...
     Safety: The study reported an acceptable safety profile for baricitinib in combination w...

  5. [PMC] Rapid response of lichen planus to baricitinib associat...
     PASS: Disease=Cutaneous lichen planus, N=12, Response=83.3%
     Efficacy: Baricitinib demonstrated high efficacy in cutaneous lichen planus with 83.3% of ...
     Safety: Treatment was well tolerated with 12 total adverse events, mostly mild or modera...

  6. [PMC] Clinical experience and safety of Janus kinase inhibito...
     PASS: Disease=Giant Cell Arteritis, N=15, Response=73.0%
     Efficacy: JAK inhibitors showed significant efficacy in treating GCA with sustained reduct...
     Safety: Two patients experienced serious infections but JAK inhibitor therapy was retain...

  7. [PMC] Efficacy and safety of baricitinib in Japanese patients...
     PASS: Disease=Autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, AGS), N=9, Response=None%
     Efficacy: Baricitinib showed clinical benefit in NNS/CANDLE and SAVI patients with decreas...
     Safety: All patients experienced at least one adverse event. Three patients had serious ...

  8. [PMC] Long-term Outcomes of New Systemic Agents in Atopic Der...
     PASS: Disease=atopic dermatitis, N=62, Response=None%
     Efficacy: Baricitinib showed the lowest 18-month drug survival rate at 20.4% among all tre...
     Safety: Of the 44 patients who discontinued baricitinib, 11 (17.7%) discontinued due to ...

  9. [PMC] Baricitinib could improve the prognosis of anti-MDA5 an...
     PASS: Disease=Anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease, N=39, Response=79.5%
     Efficacy: Baricitinib showed significant improvement in clinical symptoms, lung function, ...
     Safety: Safety outcomes were not explicitly reported in detail in this retrospective stu...

  10. [PMC] Baricitinib for refractory Takayasu arteritis: a prospe...
     PASS: Disease=Takayasu arteritis, N=10, Response=60.0%
     Efficacy: Baricitinib 4 mg daily achieved overall treatment response in 60% of refractory ...
     Safety: Baricitinib was well tolerated with only one patient (10%) discontinuing due to ...

  11. [PMC] Alopecia Areata Following the Use of Belimumab in a Pat...
     PASS: Disease=Systemic Lupus Erythematosus with Arthritis, N=1, Response=100.0%
     Efficacy: Baricitinib resulted in significant improvement in both alopecia totalis and art...
     Safety: No adverse events were reported with baricitinib treatment in this case report....

  12. [PMC] Drug Survival and Predictors of Systemic Treatment Outc...
     PASS: Disease=Atopic Dermatitis, N=30, Response=None%
     Efficacy: Baricitinib showed poor drug survival in atopic dermatitis with only 14.2% of pa...
     Safety: Safety data not specifically reported for baricitinib alone. Side effects were c...

  13. [PMC] Case report: Effectiveness of Janus kinase inhibitors i...
     PASS: Disease=isolated noninfectious uveitis, N=3, Response=100.0%
     Efficacy: All three patients with refractory isolated noninfectious uveitis achieved compl...
     Safety: No significant side effects were observed in any patients throughout the follow-...

  14. [PMC] Use of Baricitinib in a patient with treatment-resistan...
     PASS: Disease=pyoderma gangrenosum, N=1, Response=100.0%
     Efficacy: Baricitinib 4mg daily for 12 weeks led to complete resolution of ulcers on right...
     Safety: Patient developed septic arthritis after discontinuation of baricitinib, though ...

  15. [PMC] Safety and efficacy of off-label bulevirtide monotherap...
     WARN: No data extracted

  16. [PMC] Use, access, and initial outcomes of off-label ivosiden...
     WARN: No data extracted

  17. [PMC] A case of hemophagocytic lymphohistiocytosis with a sig...
     PASS: Disease=Hemophagocytic lymphohistiocytosis, N=1, Response=100.0%
     Efficacy: Single patient with HLH showed significant response to baricitinib treatment. Th...
     Safety: No safety information provided in the available case report details....

  18. [PMC] Successful Treatment of Refractory Synovitis, Acne, Pus...
     PASS: Disease=SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis), N=1, Response=100.0%
     Efficacy: Baricitinib achieved rapid and complete resolution of both skin lesions and oste...
     Safety: No adverse effects were observed during treatment or follow-up period. The patie...

  19. [PMC] Efficacy of Baricitinib in Patients with Refractory Adu...
     PASS: Disease=Adult-onset Still's disease (AOSD), N=7, Response=85.7%
     Efficacy: Baricitinib provided rapid and durable clinical improvement in 6/7 patients with...
     Safety: Treatment was generally well tolerated with mild lipid abnormalities being the m...

  20. [PMC] Baricitinib is potentially effective in the treatment o...
     PASS: Disease=livedoid vasculopathy, N=8, Response=75.0%
     Efficacy: All 8 patients showed significant clinical improvement with statistically signif...
     Safety: No adverse events were reported in any patient during follow-up. Treatment was w...

  21. [PMC] Effectiveness of Baricitinib in Refractory Seronegative...
     PASS: Disease=Uveitis (bilateral non-granulomatous panuveitis), N=1, Response=100.0%
     Efficacy: Baricitinib achieved complete resolution of refractory uveitis symptoms includin...
     Safety: No serious side effects of oral baricitinib were observed or reported during the...

  22. [PMC] Case report: Dupilumab therapy for alopecia areata in a...
     PASS: Disease=Alopecia Universalis (pediatric), N=1, Response=0.0%
     Efficacy: Baricitinib showed no efficacy in this 4-year-old patient with alopecia universa...
     Safety: No adverse events reported during baricitinib treatment. Patient was switched to...

  23. [PMC] Mixed results with baricitinib in biological-resistant ...
     PASS: Disease=Adult-onset Still's disease (AOSD) and undifferentiated systemic autoinflammatory disease, N=3, Response=67.0%
     Efficacy: Mixed results with baricitinib showing complete remission in 2 of 3 patients wit...
     Safety: One serious opportunistic infection (Pneumocystis jirovecii pneumonia) occurred ...

  24. [PMC] Clinical and immunological study of Tofacitinib and Bar...
     PASS: Disease=Blau syndrome, N=1, Response=100.0%
     Efficacy: Baricitinib successfully maintained disease control after tofacitinib discontinu...
     Safety: Baricitinib showed an adequate safety profile with mild lymphopenia observed at ...

  25. [PMC] Baricitinib in severe and refractory peripheral ulcerat...
     PASS: Disease=Peripheral ulcerative keratitis (PUK), N=1, Response=100.0%
     Efficacy: Patient achieved complete ocular and joint remission within 2 weeks of baricitin...
     Safety: Treatment was well tolerated with only mild alopecia reported as an adverse effe...

--- Validation ---
  Successful: 23/25

================================================================================
 TAB 4: SCORING & PRIORITIZATION
================================================================================

  Scoring 23 extractions...

  Standardizing disease names...
  Standardized 21 disease names
  Unique diseases after standardization: 18

  Fetching market intelligence for each disease...
  (This requires web search for epidemiology & standard of care)
  Market data fetched for 22/23 diseases

--- Scored Opportunities ---

  1. systemic lupus erythematosus
     Clinical:  7.0/10 (50% weight)
     Evidence:  5.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     6.8/10

  2. Toxic epidermal necrolysis (TEN)
     Clinical:  9.5/10 (50% weight)
     Evidence:  6.3/10 (25% weight)
     Market:    6.3/10 (25% weight)
     TOTAL:     7.9/10

  3. vitiligo
     Clinical:  7.0/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    9.0/10 (25% weight)
     TOTAL:     7.5/10

  4. moderate to severe atopic dermatitis
     Clinical:  5.5/10 (50% weight)
     Evidence:  7.7/10 (25% weight)
     Market:    7.0/10 (25% weight)
     TOTAL:     6.4/10

  5. Cutaneous lichen planus
     Clinical:  10.0/10 (50% weight)
     Evidence:  6.3/10 (25% weight)
     Market:    9.7/10 (25% weight)
     TOTAL:     9.0/10

  6. Giant Cell Arteritis
     Clinical:  6.0/10 (50% weight)
     Evidence:  8.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     7.2/10

  7. Autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, AGS)
     Clinical:  4.0/10 (50% weight)
     Evidence:  5.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     5.5/10

  8. atopic dermatitis
     Clinical:  2.0/10 (50% weight)
     Evidence:  10.0/10 (25% weight)
     Market:    6.0/10 (25% weight)
     TOTAL:     5.0/10

  9. Anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease
     Clinical:  6.5/10 (50% weight)
     Evidence:  8.3/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     7.4/10

  10. Takayasu arteritis
     Clinical:  6.0/10 (50% weight)
     Evidence:  7.0/10 (25% weight)
     Market:    7.3/10 (25% weight)
     TOTAL:     6.6/10

  11. Systemic Lupus Erythematosus with Arthritis
     Clinical:  7.5/10 (50% weight)
     Evidence:  5.3/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     7.2/10

  12. Atopic Dermatitis
     Clinical:  3.0/10 (50% weight)
     Evidence:  9.3/10 (25% weight)
     Market:    6.0/10 (25% weight)
     TOTAL:     5.3/10

  13. isolated noninfectious uveitis
     Clinical:  10.0/10 (50% weight)
     Evidence:  3.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.0/10

  14. pyoderma gangrenosum
     Clinical:  5.5/10 (50% weight)
     Evidence:  2.0/10 (25% weight)
     Market:    8.0/10 (25% weight)
     TOTAL:     5.2/10

  15. Hemophagocytic lymphohistiocytosis
     Clinical:  7.5/10 (50% weight)
     Evidence:  2.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     6.5/10

  16. SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis)
     Clinical:  10.0/10 (50% weight)
     Evidence:  2.7/10 (25% weight)
     Market:    9.3/10 (25% weight)
     TOTAL:     8.0/10

  17. Adult-onset Still's disease (AOSD)
     Clinical:  7.0/10 (50% weight)
     Evidence:  5.3/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     6.9/10

  18. livedoid vasculopathy
     Clinical:  9.0/10 (50% weight)
     Evidence:  3.0/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     7.3/10

  19. Uveitis (bilateral non-granulomatous panuveitis)
     Clinical:  10.0/10 (50% weight)
     Evidence:  4.3/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     8.2/10

  20. Alopecia Universalis (pediatric)
     Clinical:  5.5/10 (50% weight)
     Evidence:  3.3/10 (25% weight)
     Market:    9.0/10 (25% weight)
     TOTAL:     5.8/10

  21. Adult-onset Still's disease (AOSD) and undifferentiated systemic autoinflammatory disease
     Clinical:  5.0/10 (50% weight)
     Evidence:  4.7/10 (25% weight)
     Market:    8.3/10 (25% weight)
     TOTAL:     5.8/10

  22. Blau syndrome
     Clinical:  10.0/10 (50% weight)
     Evidence:  2.7/10 (25% weight)
     Market:    8.0/10 (25% weight)
     TOTAL:     7.7/10

  23. Peripheral ulcerative keratitis (PUK)
     Clinical:  10.0/10 (50% weight)
     Evidence:  4.3/10 (25% weight)
     Market:    5.7/10 (25% weight)
     TOTAL:     7.5/10

--- Validation ---
  Scored: 23/23

================================================================================
 TAB 5: FULL ANALYSIS SUMMARY
================================================================================

  Drug: baricitinib
  Mechanism: Janus Kinase Inhibitor
  Approved Indications: 4
  Papers Found: 46
  Papers with PMC Full Text: 25
  Extractions: 23

--- Top Off-Label Indications ---
    atopic dermatitis: 6 papers
    systemic lupus erythematosus: 3 papers
    adult-onset Still's disease: 3 papers
    juvenile idiopathic arthritis: 2 papers
    vitiligo: 2 papers
    atopic dermatitis (pediatric): 2 papers
    toxic epidermal necrolysis: 1 papers
    type 1 diabetes: 1 papers
    polymyalgia rheumatica: 1 papers
    lichen planus: 1 papers

--- Validation ---
  PASS: Full pipeline executed

================================================================================
 FINAL SUMMARY
================================================================================
  Tab 1 Drug Info:   PASS
  Tab 2 Search:      PASS (46 papers)
  Tab 3 Extraction:  PASS (23 successful)
  Tab 4 Scoring:     PASS (23 scored)
  Tab 5 Analysis:    PASS

  Total API Tokens: 368,126
  Completed: 2025-12-05 19:35:14.368198

  JSON data saved to: test_outputs\workflow_data_20251205_190957.json

================================================================================
 GENERATING FINAL REPORT
================================================================================
  Excel report: data\case_series\baricitinib_report_20251205_190957.xlsx
  Full JSON: data\case_series\baricitinib_full_20251205_190957.json
